AI assistant
Sending…
Salarius Pharmaceuticals, Inc. — Director's Dealing 2016
Nov 7, 2016
35494_dirs_2016-11-07_3f4ff99a-607a-4584-9335-3135332236d5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2016-11-07
Reporting Person: McCabe John P. (VP of Finance & Treasurer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-11-07 | Common Stock | P | 1650 | $6.01 | Acquired | 1650 | Direct |
Footnotes
F1: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $5.99 to $6.01. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
More from Salarius Pharmaceuticals, Inc.
Regulatory Filings
2026
May 19
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Declaration of Voting Results & Voting Rights Announcements
2026
Feb 25
Major Shareholding Notification
2026
Feb 17
Proxy Solicitation & Information Statement
2026
Jan 9
Regulatory Filings
2026
Jan 8
Delisting Announcement
2026
Jan 2
Director's Dealing
2026
Jan 2